VIDEO: SABCS 2014 roundtable with Dr. William J. Gradishar and Dr. Hope S. Rugo

SAN ANTONIO – The Oncology Report associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss highlights presented at the 2014 San Antonio Breast Cancer Symposium.

First reports on checkpoint inhibitors for the treatment of breast cancer, the unique study issues to consider in investigating these immunotherapy options, disappointing results from the FERGI trial, which looked at a combination therapy with a PI3 kinase inhibitor, and overall survival data from the FIRST trial of endocrine therapy with fulvestrant for patients with advanced disease were some of the topics Dr. Gradishar and Dr. Rugo weighed in on during the discussion.

The TNT trial comparing carboplatin to docetaxel in treating patients with triple-negative breast cancer; the latest results from the SOFT trial, looking at ovarian suppression in combination with either an aromatase inhibitor or tamoxifen; and the mixed results from BOLERO-1 looking at the addition of an mTOR inhibitor to the treatment of patients with advanced HER2-positive disease were also discussed.

Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology at the Northwestern University, Chicago. Dr. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.

SAN ANTONIO – The Oncology Report associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss highlights presented at the 2014 San Antonio Breast Cancer Symposium.

First reports on checkpoint inhibitors for the treatment of breast cancer, the unique study issues to consider in investigating these immunotherapy options, disappointing results from the FERGI trial, which looked at a combination therapy with a PI3 kinase inhibitor, and overall survival data from the FIRST trial of endocrine therapy with fulvestrant for patients with advanced disease were some of the topics Dr. Gradishar and Dr. Rugo weighed in on during the discussion.

The TNT trial comparing carboplatin to docetaxel in treating patients with triple-negative breast cancer; the latest results from the SOFT trial, looking at ovarian suppression in combination with either an aromatase inhibitor or tamoxifen; and the mixed results from BOLERO-1 looking at the addition of an mTOR inhibitor to the treatment of patients with advanced HER2-positive disease were also discussed.

Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology at the Northwestern University, Chicago. Dr. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.

SAN ANTONIO – The Oncology Report associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss highlights presented at the 2014 San Antonio Breast Cancer Symposium.

First reports on checkpoint inhibitors for the treatment of breast cancer, the unique study issues to consider in investigating these immunotherapy options, disappointing results from the FERGI trial, which looked at a combination therapy with a PI3 kinase inhibitor, and overall survival data from the FIRST trial of endocrine therapy with fulvestrant for patients with advanced disease were some of the topics Dr. Gradishar and Dr. Rugo weighed in on during the discussion.

The TNT trial comparing carboplatin to docetaxel in treating patients with triple-negative breast cancer; the latest results from the SOFT trial, looking at ovarian suppression in combination with either an aromatase inhibitor or tamoxifen; and the mixed results from BOLERO-1 looking at the addition of an mTOR inhibitor to the treatment of patients with advanced HER2-positive disease were also discussed.

Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology at the Northwestern University, Chicago. Dr. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.